Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
The present invention provides an antibody or antigen-binding fragment thereof that binds α V β 3 integrin, as well as methods of use in the treatment of diseases and disorders.
1. An isolated antibody or antigen-binding fragment thereof that binds the α v β 3 integrin cysteine loop (C-loop) domain of SEQ ID NO: 29, wherein the antibody or antigen-binding fragment thereof comprises the light chain complementarity determining region (CDR) sequences LCDR1 of SEQ ID NO:1 (KSSQSLLYSSNQKNYLA); LCDR2 of SEQ ID NO:2 (WASTRES); and LCDR3 of SEQ ID NO:3 (KQYYTYPLT) and the heavy chain complementarity determining region (CDR) sequences HCDR1 of SEQ ID NO:4 (NSWMN); HCDR2 of SEQ ID NO:5 (IFPGDGDTNYNGKFKG) and HCDR3 of SEQ ID NO:6 (WGLTRDRRLYLDY).
2. An isolated antibody or antigen-binding fragment thereof that binds α v β 3 integrin, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:12 (VH6) and a light chain comprising the amino acid sequence of SEQ ID NO:14 (Vκ2).
3. An isolated antibody or antigen-binding fragment thereof that binds α v β 3 integrin, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:11 (VH5) and a light chain comprising the amino acid sequence of SEQ ID NO:14 (Vκ2).
4. An isolated antibody or antigen-binding fragment thereof that binds α v β 3 integrin, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:17 (VH6) and a light chain comprising the amino acid sequence of SEQ ID NO:16 (Vκ2).
5. An isolated antibody or antigen-binding fragment thereof that binds α v β 3 integrin, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:28 (VH5) and a light chain comprising the amino acid sequence of SEQ ID NO:16 (Vκ2).